Patents by Inventor Hans-Ludwig Schafer

Hans-Ludwig Schafer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10995150
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 4, 2021
    Assignees: REGENERON PHARMACEUTICALS, INC., SANOFI BIOTECHNOLOGY
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
  • Publication number: 20200071422
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Application
    Filed: July 8, 2019
    Publication date: March 5, 2020
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
  • Patent number: 10494442
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: December 3, 2019
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
  • Publication number: 20100160282
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: December 23, 2009
    Publication date: June 24, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Heiner Glombik, Werner Kramer, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Patent number: 7674773
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: March 9, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Kramer, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Patent number: 7576200
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: August 18, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Publication number: 20090143473
    Abstract: Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids. The active compounds identified as inhibitors of the cellular Na+/H+ exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids. They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as the endothelial dysfunction syndrome and illness caused thereby.
    Type: Application
    Filed: February 3, 2009
    Publication date: June 4, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hans Jochen LANG, Hans-Willi JANSEN, Jan-Robert SCHWARK, Heinz-Werner KLEEMANN, Oliver JUNG, Hans-Ludwig SCHAFER, Wolfgang LINZ, Werner KRAMER, Bernward SCHOLKENS, Eugen FALK
  • Patent number: 7488829
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 10, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Publication number: 20080281092
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: July 17, 2008
    Publication date: November 13, 2008
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schafer
  • Patent number: 7399777
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: July 15, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schäfer, Lothar Schwink, Wolfgang Wendler
  • Publication number: 20070208179
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: May 7, 2007
    Publication date: September 6, 2007
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schafer
  • Patent number: 6992067
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: January 31, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Publication number: 20050267177
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
    Type: Application
    Filed: April 4, 2005
    Publication date: December 1, 2005
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schafer, Lothar Schwink, Wolfgang Wendler
  • Publication number: 20050267038
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: June 17, 2005
    Publication date: December 1, 2005
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schafer
  • Patent number: 6897198
    Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described. Also described are compounds of formula I in which the radicals have the abovementioned meanings, and their physiologically tolerated salts, physiologically functional derivates and processes for their preparation. The compounds are suitable as, for example, hypolipidemics.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Wendelin Frick, Reinhard Kirsch, Heiner Glombik, Werner Kramer, Hans-Ludwig Schäfer
  • Patent number: 6884812
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 26, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schäfer, Lothar Schwink, Wolfgang Wendler
  • Publication number: 20040122069
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed.
    Type: Application
    Filed: August 1, 2003
    Publication date: June 24, 2004
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schafer, Lothar Schwink, Wolfgang Wendler
  • Publication number: 20040122096
    Abstract: Use of inhibitors of cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids
    Type: Application
    Filed: October 8, 2003
    Publication date: June 24, 2004
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Hans Jochen Lang, Hans-Willi Jansen, Jan-Robert Schwark, Heinz-Werner Kleemann, Oliver Jung, Hans-Ludwig Schafer, Wolfgang Linz, Werner Kramer, Bernward Scholkens, Eugen Falk
  • Publication number: 20030195145
    Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described.
    Type: Application
    Filed: January 27, 2003
    Publication date: October 16, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Wendelin Frick, Reinhard Kirsch, Heiner Glombik, Werner Kramer, Hans-Ludwig Schafer
  • Patent number: 6624185
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: September 23, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schäfer, Lothar Schwink, Wolfgang Wendler